α-Glucosidase-IN-16 is a highly effective and orally bioavailable inhibitor of α-glucosidase, displaying a remarkable IC50 value of 3.28 μM. This compound significantly decreases blood glucose levels in Streptozotocin-induced diabetic rats and exhibits noteworthy antidiabetic activity [1].

α-Glucosidase-IN-16 (compound 13B), administered orally at 10 and 20 mg/kg daily for 28 days, significantly reduces blood glucose levels in diabetic Wistar rats (170-200 g, 8-10 weeks old) induced by Streptozotocin injection, with no toxicity at 2000 mg/kg in Balb/C mice. It lowers serum glucose to 110-113 mg/dL compared to 128 mg/dL in controls after a single oral dose. Over 28 days, blood glucose levels consistently decrease to 132.98 ± 4.33 mg/dL and 108.42 ± 3.98 mg/dL for the 10 and 20 mg/kg doses, respectively. Additionally, α-Glucosidase-IN-16 reduces total cholesterol, suggesting benefits for diabetic and hypercholesterolemic conditions.